Popović J
Ther Drug Monit. 1984;6(1):77-82.
A method for determination of metoclopramide in serum, urine, and saliva is described that can be applied to both pharmacokinetic and clinical studies. Metoclopramide was extracted from alkalinised plasma into dichloromethane and chromatographed on a Micro-Pak Si-5 column using a mobile phase of dichloromethane/methanol/diethylamine (89:10:1, by volume). The column was maintained at 25 degrees C and the eluate monitored at 308 nm. The retention time for metoclopramide was 4.7 min. The limit of sensitivity in serum and urine was 15 nmol/L and 3 mumol/L, respectively, with coefficients of variation of 5.4 and 3.84%, respectively. Recovery was in the range of 93-110% for serum and 94-103% for urine. The limit of sensitivity in saliva was 15 nmol/L. In more than 210 samples analyzed to date, the only drugs known to have interfered with the assay are beta-adrenoceptor blockers (e.g., propranolol). The metabolites of metoclopramide did not interfere with the quantitation of the parent drug.
本文描述了一种测定血清、尿液和唾液中胃复安的方法，该方法可应用于药代动力学和临床研究。胃复安从碱化血浆中萃取至二氯甲烷中，并在Micro-Pak Si-5柱上进行色谱分析，流动相为二氯甲烷/甲醇/二乙胺（体积比89:10:1）。色谱柱温度维持在25℃，洗脱液于308nm处进行监测。胃复安的保留时间为4.7分钟。血清和尿液中的检测灵敏度极限分别为15nmol/L和3μmol/L，变异系数分别为5.4%和3.84%。血清回收率为93%-110%，尿液回收率为94%-103%。唾液中的检测灵敏度极限为15nmol/L。在迄今分析的210多个样本中，已知仅β-肾上腺素受体阻滞剂（如普萘洛尔）会干扰该测定。胃复安的代谢产物不干扰母体药物的定量分析。
